GMDA News and Press, Gamida Cell Ltd. From 08/01/22

The U.S. Food and Drug Administration (FDA) granted priority review to Gamida Cell's ( NASDAQ: GMDA ) application seeking approval of stem cell therapy omidubicel to treat patients with blood cancers in need of an allogenic hematopoietic stem cell transplant. The ...

- If approved, omidubicel will be the first allogeneic advanced stem cell therapy donor source for patients with blood cancers in need of a stem cell transplant - - PDUFA target action date is January 30, 2023 - - Company to host conference call on BLA acceptan...

The following slide deck was published by Gamida Cell Ltd. in conjunction with this event. For further details see: Gamida Cell (GMDA) Investor Presentation- Slideshow

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Heart Test Laboratories ( HSCS ) stock leads out gainers after its public debut. Cango (NYSE: CANG ) stock tops out losers following a recent earnings report. One stock is heading higher despite bankruptcy ...

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces that company management will present its corporate highlights at the JMP Securities Life Scienc...

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces the appointment of Ivan M. Borrello, M.D. to its Board of Directors, effective June 9, 2022. Dr...

Gamida Cell (NASDAQ:GMDA +6.5%) said on Thursday it had completed the rolling submission of a Biologics License Application for omidubicel, a treatment for patients with blood cancers in need of stem cell transplant. The FDA has 60 days to determine whether the BLA for omidubicel is acceptabl...

- Omidubicel is a first-in-class, advanced NAM-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for patients with blood cancers in need of a transplant – - Omidubicel has Orphan Drug Designation...

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, announces that company management will present its corporate highlights at the Jefferies Healthcare Confe...

Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, today announced the activation of the initial clinical sites to screen and enroll patients in the company...